Stryker (NYSE:SYK) Receives “Market Perform” Rating from JMP Securities

Stryker (NYSE:SYK)‘s stock had its “market perform” rating reissued by stock analysts at JMP Securities in a research report issued on Tuesday,Benzinga reports.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group raised their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Evercore ISI increased their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. BTIG Research upped their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, Citigroup lifted their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Price Performance

SYK traded down $2.47 during trading on Tuesday, reaching $382.71. The stock had a trading volume of 167,073 shares, compared to its average volume of 1,385,474. The business has a 50-day moving average of $377.39 and a 200-day moving average of $367.56. The stock has a market cap of $145.90 billion, a PE ratio of 49.36, a PEG ratio of 2.98 and a beta of 0.96. Stryker has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company posted $3.46 EPS. As a group, equities research analysts anticipate that Stryker will post 13.49 EPS for the current fiscal year.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Stryker

Several hedge funds and other institutional investors have recently bought and sold shares of SYK. J. W. Coons Advisors LLC lifted its holdings in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC boosted its position in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock worth $53,000 after purchasing an additional 27 shares during the last quarter. Opal Wealth Advisors LLC grew its stake in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after purchasing an additional 28 shares during the period. Lindbrook Capital LLC lifted its stake in shares of Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock worth $507,000 after purchasing an additional 28 shares during the period. Finally, Alhambra Investment Management LLC increased its stake in shares of Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after purchasing an additional 29 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.